GLP1R and type 2 diabetes mellitus: In conclusion, the small differences in variabilities of time to death between verum and placebo arms of ten large CVOTs and the absence of predictors for treatment heterogeneity suggest a low potential for the precision treatment approach for reducing all-cause mortality in the treatment of type 2 diabetes, at least for DPP-4 inhibitors, GLP-1 receptor agonists, and SGLT-2 inhibitors.